These four cell lines thus represent diverse gallbladder cancer sub‐classes based on their KRAS mutant allele status.37 Of note, KRAS mutations are known to predict plural clinical outcome in response to EGFR inhibitors in colorectal and lung cancer along with other mutations (Supporting Information Table S4).41, 42. This evidence concerns the gene KRAS and lung cancer.